Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04434040
Title Ipatasertib + Atezolizumab to Prevent Recurrence in TNBC
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute

triple-receptor negative breast cancer


Atezolizumab + Ipatasertib

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.